{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:00:59Z","timestamp":1781920859468,"version":"3.54.5"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Significant advances in the treatment of pulmonary arterial hypertension (PAH) over the last two decades have led to the introduction of multiple classes of oral therapy, but the disease remains devastating for many patients. Disease progression, in spite of oral monotherapy, is a major problem, and alternative therapy, such as infusion of prostacyclins, is cumbersome and carries considerable potential morbidity. Use of combination oral therapy, including drugs from both the endothelin receptor antagonist and phosphodiesterase-5 inhibitor classes, has increased, and there is some evidence to support this approach. Given the multiple options now available in pulmonary hypertension (PH) therapy, biomarkers to guide treatment decisions could be helpful. Here, we review the evidence for and against the clinical use of molecular biomarkers relevant to PH pathogenesis, emphasizing assayable markers that may also inform more rational selection of agents that influence pathways targeted by treatment. We emphasize the interactive nature of changes in mediators and messengers, such as endothelin-1, prostacyclin, brain natriuretic peptide (which has demonstrated biomarker utility), nitric oxide derivatives, and cyclic guanosine monophosphate, which play important roles in processes central to progression of PAH, such as vascular remodeling, vasoconstriction, and maladaptive right ventricular changes, and are relevant to its therapy. Accordingly, we propose that the identification and use of a molecular biomarker panel that assays these molecules in parallel and serially might, if validated, better inform unique patient phenotypes, prognosis, and the rational selection and titration of combination oral and other therapy in individual patients with PH\/PAH.<\/jats:p>","DOI":"10.1165\/rcmb.2014-0438tr","type":"journal-article","created":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T14:58:17Z","timestamp":1421938697000},"page":"663-673","source":"Crossref","is-referenced-by-count":22,"title":["Treatment-Related Biomarkers in Pulmonary Hypertension"],"prefix":"10.1093","volume":"52","author":[{"given":"Aparna C.","family":"Swaminathan","sequence":"first","affiliation":[{"name":"Duke University and Durham Department of Veterans Affairs Medical Centers, Durham, North Carolina; and"},{"name":"Bayer HealthCare, Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Dusek","sequence":"additional","affiliation":[{"name":"Duke University and Durham Department of Veterans Affairs Medical Centers, Durham, North Carolina; and"},{"name":"Bayer HealthCare, Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"McMahon","sequence":"additional","affiliation":[{"name":"Duke University and Durham Department of Veterans Affairs Medical Centers, Durham, North Carolina; and"},{"name":"Bayer HealthCare, Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,6,1]]},"reference":[{"key":"2026021122311085000_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1164\/rccm.201311-1954ST","article-title":"An official American Thoracic Society statement: pulmonary hypertension phenotypes","volume":"189","author":"Dweik","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1378\/chest.14-0793","article-title":"Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report","volume":"146","author":"Taichman","year":"2014","journal-title":"Chest"},{"key":"2026021122311085000_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"key":"2026021122311085000_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/ajrccm.161.3.9906051","article-title":"Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33","volume":"161","author":"Deng","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib8","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMct0904473","article-title":"Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension","volume":"361","author":"Archer","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib9","first-page":"2894","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume-title":"Circulation","author":"Gali\u00e8","year":"2009"},{"key":"2026021122311085000_bib10","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib14","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"2026021122311085000_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"2026021122311085000_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026021122311085000_bib18","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026021122311085000_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"2026021122311085000_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"2026021122311085000_bib22","doi-asserted-by":"crossref","first-page":"860A","DOI":"10.1378\/chest.1992777","article-title":"Effect of bosentan and sildenafil combination therapy on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the COMPASS-2 study [abstract]","volume":"146","author":"McLaughlin","year":"2014","journal-title":"Chest"},{"issue":"Suppl 58","key":"2026021122311085000_bib23","first-page":"2916","article-title":"AMBITION: a randomised, multicentre study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH)","volume":"44","author":"Gali\u00e8","year":"2014","journal-title":"Eur Respir J"},{"key":"2026021122311085000_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib25","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"2026021122311085000_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026021122311085000_bib27"},{"key":"2026021122311085000_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Gali\u00e8","year":"2009","journal-title":"Eur Respir J"},{"issue":"25 suppl","key":"2026021122311085000_bib29","doi-asserted-by":"crossref","first-page":"D73","DOI":"10.1016\/j.jacc.2013.10.034","article-title":"Treatment goals of pulmonary hypertension","volume":"62","author":"McLaughlin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026021122311085000_bib30","first-page":"2355","article-title":"Comparison of current therapies to inhibit endothelin-induced growth of pulmonary artery smooth muscle cells (PAMSCs) derived from patients with pulmonary arteiral hypertension","volume":"44","author":"Patel","year":"2014","journal-title":"Eur Resp Society"},{"key":"2026021122311085000_bib31","first-page":"A3324","article-title":"Ambrisentan and riociguat synergistically relax endothelin-induced contraction of rat pulmonary arteries [abstract]","volume":"189","author":"Liang","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201304-0686PP","article-title":"Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension","volume":"188","author":"Klinger","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6 suppl","key":"2026021122311085000_bib34","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1016\/j.amjcard.2012.06.014","article-title":"The potential of biomarkers in pulmonary arterial hypertension","volume":"110","author":"Cracowski","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026021122311085000_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-1246","article-title":"Biomarkers in pulmonary hypertension: what do we know?","volume":"144","author":"Foris","year":"2013","journal-title":"Chest"},{"key":"2026021122311085000_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1183\/09031936.00160307","article-title":"Biomarkers in pulmonary hypertension","volume":"32","author":"Warwick","year":"2008","journal-title":"Eur Respir J"},{"key":"2026021122311085000_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1742-1241.2009.02117.x","article-title":"Biomarkers in pulmonary arterial hypertension","volume":"162","author":"Rafeq","year":"2009","journal-title":"Int J Clin Pract Suppl"},{"key":"2026021122311085000_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1742-1241.2010.02598.x","article-title":"Clinical perspective: biomarkers in pulmonary arterial hypertension","volume":"169","author":"Heresi","year":"2011","journal-title":"Int J Clin Pract Suppl"},{"key":"2026021122311085000_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/157339812799859770","article-title":"Biomarkers of lung tissue remodeling in pulmonary diseases: implications for clinical practice and research","volume":"8","author":"Kramer","year":"2012","journal-title":"Curr Respir Med Rev"},{"key":"2026021122311085000_bib40","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1164\/rccm.200608-1189OC","article-title":"Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling","volume":"175","author":"Taraseviciene-Stewart","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib41","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1161\/CIRCULATIONAHA.108.769646","article-title":"Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension","volume":"117","author":"Diller","year":"2008","journal-title":"Circulation"},{"key":"2026021122311085000_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2353\/ajpath.2006.050599","article-title":"Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte\/macrophage lineage","volume":"168","author":"Frid","year":"2006","journal-title":"Am J Pathol"},{"key":"2026021122311085000_bib43","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J Clin Invest"},{"key":"2026021122311085000_bib44","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm954","article-title":"Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation","volume":"9","author":"Cosby","year":"2003","journal-title":"Nat Med"},{"key":"2026021122311085000_bib45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1073\/pnas.0233287100","article-title":"Routes to S-nitroso-hemoglobin formation with heme redox and preferential reactivity in the beta subunits","volume":"100","author":"Luchsinger","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026021122311085000_bib46","first-page":"97","article-title":"Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery","volume":"22","author":"Sonveaux","year":"2007","journal-title":"Physiology (Bethesda)"},{"key":"2026021122311085000_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8","article-title":"High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension","volume":"185","author":"Mason","year":"1998","journal-title":"J Pathol"},{"key":"2026021122311085000_bib48","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1096\/fj.04-3223fje","article-title":"Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension","volume":"19","author":"Pullamsetti","year":"2005","journal-title":"FASEB J"},{"key":"2026021122311085000_bib49","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/01.ATV.0000168414.06853.f0","article-title":"Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension","volume":"25","author":"Kielstein","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021122311085000_bib50","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1164\/rccm.200702-278OC","article-title":"Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension","volume":"176","author":"Skoro-Sajer","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib51","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(01)07184-7","article-title":"Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine","volume":"358","author":"Valkonen","year":"2001","journal-title":"Lancet"},{"key":"2026021122311085000_bib52","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"},{"key":"2026021122311085000_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1152\/jappl.1995.78.1.59","article-title":"Exhaled nitric oxide in isolated pig lungs","volume":"78","author":"Cremona","year":"1995","journal-title":"J Appl Physiol (1985)"},{"key":"2026021122311085000_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1378\/chest.111.1.44","article-title":"Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis","volume":"111","author":"Riley","year":"1997","journal-title":"Chest"},{"key":"2026021122311085000_bib55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/ajrccm.158.3.9802066","article-title":"Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension","volume":"158","author":"Kaneko","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib56","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/thx.52.12.1051","article-title":"Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension","volume":"52","author":"Kharitonov","year":"1997","journal-title":"Thorax"},{"key":"2026021122311085000_bib57","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.158.4.9802113","article-title":"Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension","volume":"158","author":"Archer","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/cs0970099","article-title":"Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls","volume":"97","author":"Forrest","year":"1999","journal-title":"Clin Sci (Lond)"},{"key":"2026021122311085000_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s004080000064","article-title":"High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy","volume":"179","author":"Ozkan","year":"2001","journal-title":"Lung"},{"key":"2026021122311085000_bib60","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/rccm.200412-1684OC","article-title":"Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy","volume":"172","author":"Girgis","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib61","first-page":"590","article-title":"The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans","volume-title":"Biochem Biophys Res Commun","author":"Rhodes","year":"1995"},{"key":"2026021122311085000_bib62","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1440-1681.1997.tb01212.x","article-title":"Effects of diet on measurement of nitric oxide metabolites","volume":"24","author":"Wang","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026021122311085000_bib63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1994.tb12040.x","article-title":"Nitric oxide synthesis and metabolism in man","volume":"714","author":"Wennmalm","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"2026021122311085000_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpeds.2011.07.040","article-title":"Inhaled nitric oxide therapy increases blood nitrite, nitrate, and S-nitrosohemoglobin concentrations in infants with pulmonary hypertension","volume":"160","author":"Ibrahim","year":"2012","journal-title":"J Pediatr"},{"key":"2026021122311085000_bib65","doi-asserted-by":"crossref","first-page":"14801","DOI":"10.1073\/pnas.0506957102","article-title":"A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension","volume":"102","author":"McMahon","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026021122311085000_bib66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/pats.200507-066BG","article-title":"Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin","volume":"3","author":"McMahon","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"2026021122311085000_bib67","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/0002-8703(87)90663-6","article-title":"Plasma concentrations of alpha-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease","volume":"113","author":"Hirata","year":"1987","journal-title":"Am Heart J"},{"key":"2026021122311085000_bib68","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/thx.53.12.1059","article-title":"Urinary cGMP concentrations in severe primary pulmonary hypertension","volume":"53","author":"Bogdan","year":"1998","journal-title":"Thorax"},{"key":"2026021122311085000_bib69","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0735-1097(01)01490-5","article-title":"Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation","volume":"38","author":"Wiedemann","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026021122311085000_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate\u2013dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"2026021122311085000_bib71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","article-title":"Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility","volume":"116","author":"Nagendran","year":"2007","journal-title":"Circulation"},{"key":"2026021122311085000_bib72","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"2026021122311085000_bib73","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","article-title":"Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery","volume":"26","author":"Clapp","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026021122311085000_bib74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00614197","article-title":"Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man","volume":"30","author":"Krause","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"2026021122311085000_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/2045-8932.109911","article-title":"Nitric oxide deficiency in pulmonary hypertension: pathobiology and implications for therapy","volume":"3","author":"Tonelli","year":"2013","journal-title":"Pulm Circ"},{"key":"2026021122311085000_bib76","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1183\/09031936.93.03080910","article-title":"Atrial natriuretic peptide in primary pulmonary hypertension","volume":"3","author":"Morice","year":"1990","journal-title":"Eur Respir J"},{"key":"2026021122311085000_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/cs0950235","article-title":"Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice","volume":"95","author":"Buckley","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"2026021122311085000_bib78","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0003-4975(02)03654-8","article-title":"Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy","volume":"74","author":"Nagaya","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"2026021122311085000_bib79","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"2026021122311085000_bib80","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1378\/chest.06-1758","article-title":"N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension","volume":"131","author":"Leuchte","year":"2007","journal-title":"Chest"},{"key":"2026021122311085000_bib81","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"2026021122311085000_bib82","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1183\/09031936.00070209","article-title":"Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension","volume":"35","author":"Sztrymf","year":"2010","journal-title":"Eur Respir J"},{"key":"2026021122311085000_bib83","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.amjcard.2011.07.025","article-title":"Usefulness of serial N-terminal pro-B\u2013type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension","volume":"108","author":"Mauritz","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026021122311085000_bib84","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201401-0065ST","article-title":"An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease","volume":"189","author":"Klings","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021122311085000_bib85","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib86","first-page":"248","article-title":"Phosphodiesterases and cyclic GMP regulation in heart muscle","volume":"27","author":"Lee","year":"2012","journal-title":"Physiology (Bethesda)"},{"key":"2026021122311085000_bib87","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0167-0115(94)00119-I","article-title":"Metabolism of Big endothelin-1 (1\u201338) and (22\u201338) in the human circulation in relation to production of endothelin-1 (1\u201321)","volume":"55","author":"Hems\u00e9n","year":"1995","journal-title":"Regul Pept"},{"key":"2026021122311085000_bib88","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1164\/ajrccm\/148.2.519","article-title":"Circulating immunoreactive endothelin-1 in children with pulmonary hypertension: association with acute hypoxic pulmonary vasoreactivity","volume":"148","author":"Allen","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2026021122311085000_bib89","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"2026021122311085000_bib90","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/0002-9149(93)90646-T","article-title":"Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow","volume":"71","author":"Vincent","year":"1993","journal-title":"Am J Cardiol"},{"key":"2026021122311085000_bib91","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","article-title":"Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels","volume":"26","author":"Nootens","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026021122311085000_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.06-0682","article-title":"Endothelin-1\/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension","volume":"131","author":"Montani","year":"2007","journal-title":"Chest"},{"key":"2026021122311085000_bib93","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"2026021122311085000_bib94","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.healun.2013.06.020","article-title":"An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1","volume":"32","author":"Silva Marques","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2026021122311085000_bib95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004872-200401000-00020","article-title":"In-vivo interaction of nitric oxide and endothelin","volume":"22","author":"Hocher","year":"2004","journal-title":"J Hypertens"},{"key":"2026021122311085000_bib96","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/01.CIR.97.8.752","article-title":"Endothelin-A receptor antagonist\u2013mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade","volume":"97","author":"Verhaar","year":"1998","journal-title":"Circulation"},{"key":"2026021122311085000_bib97","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.amjcard.2009.05.016","article-title":"Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension","volume":"104","author":"Hampole","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026021122311085000_bib98","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/hrt.2011.224857","article-title":"Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension","volume":"97","author":"Rhodes","year":"2011","journal-title":"Heart"},{"key":"2026021122311085000_bib99","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/52\/6\/663\/66834160\/ajrcmb_52_6_663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/52\/6\/663\/66834160\/ajrcmb_52_6_663.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T03:31:51Z","timestamp":1770867111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/52\/6\/663\/8467730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":99,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,1]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1165\/rcmb.2014-0438tr","relation":{},"ISSN":["1044-1549","1535-4989"],"issn-type":[{"value":"1044-1549","type":"print"},{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,6]]},"published":{"date-parts":[[2015,6,1]]}}}